Department of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Toon, Japan.
J Hepatobiliary Pancreat Sci. 2023 May;30(5):591-601. doi: 10.1002/jhbp.1256. Epub 2022 Nov 8.
The Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) nomogram was developed to predict disease-free survival in patients with colorectal liver metastases (CRLM) undergoing upfront hepatectomy. However, the utility of the nomogram in patients with resected CRLM remains unknown in the current situation in which treatment strategies are changing with advances in drugs.
Patients in the initial nomogram cohort (n = 727) and validation cohort (n = 2225) were divided into the upfront hepatectomy and preoperative chemotherapy groups. The nomogram was validated by measuring calibration and discrimination in the two cohorts. Calibration curves were plotted, and survival probabilities were compared. Finally, to quantify the discrimination power, we estimated the concordance index (C-index).
In the upfront hepatectomy group, the C-index was 0.63, the suitable cutoff value of the Beppu score was 7, and adjuvant chemotherapy was significantly effective limited to high-risk patients (Beppu score ≥7). The C-index was 0.56 in the preoperative chemotherapy group.
The JSHBPS nomogram remains beneficial for patients undergoing upfront hepatectomy in the recent era but is less effective for patients undergoing hepatectomy after chemotherapy. Patients with a Beppu score ≥7 showed high-risk recurrence, and adjuvant chemotherapy should be recommended for these patients.
日本肝胆胰外科学会(JSHBPS)列线图旨在预测接受直接肝切除术的结直肠癌肝转移(CRLM)患者的无病生存率。然而,在当前药物治疗进展改变治疗策略的情况下,该列线图在接受切除术的 CRLM 患者中的实用性尚不清楚。
将初始列线图队列(n=727)和验证队列(n=2225)中的患者分为直接肝切除术和术前化疗组。通过在两个队列中测量校准和区分度来验证列线图。绘制校准曲线,并比较生存概率。最后,为了量化区分能力,我们估计了一致性指数(C-index)。
在直接肝切除术组中,C-index 为 0.63,Beppu 评分的合适截断值为 7,辅助化疗对高危患者(Beppu 评分≥7)显著有效。在术前化疗组中,C-index 为 0.56。
JSHBPS 列线图在最近的时代仍然有利于接受直接肝切除术的患者,但对接受化疗后接受肝切除术的患者效果较差。Beppu 评分≥7 的患者显示出高风险的复发,应推荐这些患者接受辅助化疗。